177 related articles for article (PubMed ID: 37027032)
21. Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis.
Lee MJ; Kuehne N; Hueniken K; Liang S; Rai S; Sorotsky H; Herman M; Shepshelovich D; Bruce J; Liang M; Patel D; Cheng D; Chen Z; Eng L; Brown MC; Cho J; Leighl NB; de Perrot M; Reisman D; Xu W; Bradbury PA; Liu G
Mol Carcinog; 2019 Nov; 58(11):1960-1973. PubMed ID: 31355511
[TBL] [Abstract][Full Text] [Related]
22. Mesothelioma, asbestos, and reported history of cancer in first-degree relatives.
Heineman EF; Bernstein L; Stark AD; Spirtas R
Cancer; 1996 Feb; 77(3):549-54. PubMed ID: 8630964
[TBL] [Abstract][Full Text] [Related]
23. Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins.
Giusti L; Da Valle Y; Bonotti A; Donadio E; Ciregia F; Ventroni T; Foddis R; Giannaccini G; Guglielmi G; Cristaudo A; Lucacchini A
Proteomics Clin Appl; 2014 Apr; 8(3-4):258-68. PubMed ID: 24415579
[TBL] [Abstract][Full Text] [Related]
24. Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals.
Attanoos RL; Thomas DH; Gibbs AR
Histopathology; 2003 Oct; 43(4):387-92. PubMed ID: 14511258
[TBL] [Abstract][Full Text] [Related]
25. Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles.
Andujar P; Lacourt A; Brochard P; Pairon JC; Jaurand MC; Jean D
J Toxicol Environ Health B Crit Rev; 2016; 19(5-6):151-172. PubMed ID: 27705546
[TBL] [Abstract][Full Text] [Related]
26. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
[TBL] [Abstract][Full Text] [Related]
27. Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.
Matullo G; Guarrera S; Betti M; Fiorito G; Ferrante D; Voglino F; Cadby G; Di Gaetano C; Rosa F; Russo A; Hirvonen A; Casalone E; Tunesi S; Padoan M; Giordano M; Aspesi A; Casadio C; Ardissone F; Ruffini E; Betta PG; Libener R; Guaschino R; Piccolini E; Neri M; Musk AW; de Klerk NH; Hui J; Beilby J; James AL; Creaney J; Robinson BW; Mukherjee S; Palmer LJ; Mirabelli D; Ugolini D; Bonassi S; Magnani C; Dianzani I
PLoS One; 2013; 8(4):e61253. PubMed ID: 23626673
[TBL] [Abstract][Full Text] [Related]
28. Non-Hodgkin Lymphoma and Pleural Mesothelioma in a Person Exposed to Asbestos.
Bianchi C; Bianchi T
Turk Patoloji Derg; 2018; 34(2):190-193. PubMed ID: 28272659
[TBL] [Abstract][Full Text] [Related]
29. Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients.
Hylebos M; Op de Beeck K; Pauwels P; Zwaenepoel K; van Meerbeeck JP; Van Camp G
Lung Cancer; 2018 Oct; 124():19-22. PubMed ID: 30268460
[TBL] [Abstract][Full Text] [Related]
30. Genetic predisposition for malignant mesothelioma: A concise review.
Betti M; Aspesi A; Sculco M; Matullo G; Magnani C; Dianzani I
Mutat Res Rev Mutat Res; 2019; 781():1-10. PubMed ID: 31416570
[TBL] [Abstract][Full Text] [Related]
31. Malignant pleural mesothelioma in Turkey, 2000-2002.
Emri S; Demir AU
Lung Cancer; 2004 Aug; 45 Suppl 1():S17-20. PubMed ID: 15261427
[TBL] [Abstract][Full Text] [Related]
32. Sarcomatoid mesothelioma: future advances in diagnosis, biomolecular assessment, and therapeutic options in a poor-outcome disease.
Galetta D; Catino A; Misino A; Logroscino A; Fico M
Tumori; 2016; 102(2):127-30. PubMed ID: 26108245
[TBL] [Abstract][Full Text] [Related]
33. FKBP5, a Modulator of Stress Responses Involved in Malignant Mesothelioma: The Link between Stress and Cancer.
Cugliari G
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175892
[TBL] [Abstract][Full Text] [Related]
34. [Molecular heterogeneity of malignant pleural mesotheliomas].
Tranchant R; Montagne F; Jaurand MC; Jean D
Bull Cancer; 2018 Jan; 105(1):35-45. PubMed ID: 29277245
[TBL] [Abstract][Full Text] [Related]
35. Detailed clinical course of a patient with rapidly progressing sarcomatoid pleural mesothelioma without p16 deletion with systemic haematogenous metastasis to soft tissues.
Mizuhashi K; Okamoto K; Nabeshima K; Kishimoto T
BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38341199
[TBL] [Abstract][Full Text] [Related]
36. Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma.
Nuvoli B; Galati R
Mol Cancer Ther; 2013 Jun; 12(6):844-52. PubMed ID: 23729401
[TBL] [Abstract][Full Text] [Related]
37. Identification of a mesothelioma phenotype.
Ohar JA; Ampleford EJ; Howard SE; Sterling DA
Respir Med; 2007 Mar; 101(3):503-9. PubMed ID: 16919927
[TBL] [Abstract][Full Text] [Related]
38. An Autopsy Case Report of Malignant Pleural Mesothelioma with Deciduoid Features.
Ushio R; Yamamoto M; Shibata Y; Ishii H; Watanabe K; Takahashi R; Sato T; Kudo M; Miyake A; Kaneko T; Ishigatsubo Y
Intern Med; 2015; 54(22):2915-7. PubMed ID: 26568009
[TBL] [Abstract][Full Text] [Related]
39. Malignant mesothelioma in Lynch syndrome: A report of two cases and a review of the literature.
Shih AR; Kradin RL
Am J Ind Med; 2019 May; 62(5):448-452. PubMed ID: 31033031
[TBL] [Abstract][Full Text] [Related]
40. Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
Torricelli F; Saxena A; Nuamah R; Neat M; Harling L; Ng W; Spicer J; Ciarrocchi A; Bille A
Eur J Cancer; 2020 Jun; 132():104-111. PubMed ID: 32339978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
